On occasion of the European Society for Medical Oncology (ESMO) congress in Berlin, Dr. Konstanze Diefenbach, Head of Radiology R&D, and Nelson Ambrogio, President Radiology at Bayer, discuss how low-dose MRI innovation is reshaping cancer imaging — combining diagnostic precision with a clear focus on the patient perspective.
A key focus is the company’s phase III QUANTI study program, evaluating a low-dose gadolinium-based contrast agent designed to deliver high diagnostic efficacy with a substantially reduced gadolinium dose. The results demonstrate consistent performance across indications including the central nervous system for all age groups, underlining Bayer’s commitment to balancing diagnostic performance with the patient perspective.
The initiative reflects a broader trend in radiology toward dose optimization and precision imaging, aligning with current regulatory and clinical guidelines advocating the lowest effective dose principle. Such innovation is particularly relevant for oncology patients undergoing repeated imaging over long treatment cycles, as well as for vulnerable populations, including pediatric and neurological cases.
Beyond MRI, Bayer continues to expand its integrated radiology portfolio — encompassing contrast media injection systems, digital workflow solutions, molecular imaging, and interventional radiology technologies — to enable earlier disease detection and support evidence-based, personalized treatment decisions.
